mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

Autores da FMUP

• Tiago Emanuel Azenha Rama

  Autor

• André Miguel Afonso De Sousa Moreira

  Autor

Participantes de fora da FMUP

• Castells, M

Unidades de investigação

• Patologia

Abstract

[No abstract available]

Keywords

• Adult; Anaphylaxis; COVID-19; COVID-19 Vaccines; Female; Humans; Mast Cells; Mastocytosis, Systemic; RNA, Messenger; SARS-CoV-2; bnt 162b 2; CD2 antigen; histamine H1 receptor antagonist; histamine H2 receptor antagonist; interleukin 2 receptor alpha; montelukast; stem cell factor receptor; tozinameran; tryptase; messenger RNA; adult; anaphylaxis; bloating; bone marrow derived mast cell; case report; cell aggregation; clinical article; colic; coronavirus disease 2019; diarrhea; direct contact transmission; disease exacerbation; drug safety; drug tolerability; female; gastroesophageal reflux; gene mutation; human; indolent systemic mastocytosis; Letter; mast cell activation syndrome; middle aged; migraine; myalgia; nurse; osteopenia; premedication; priority journal; protein blood level; pruritus; skin defect; skin pruritus; urticaria pigmentosa; vaccination; administration and dosage; adverse event; anaphylaxis; immunology; mast cell; prevention and control; systemic mastocytosis; virol